Cocrystals of quercetin with improved solubility and oral bioavailability.
暂无分享,去创建一个
Michael J Zaworotko | L. Wojtas | M. Zaworotko | R. Shytle | Lukasz Wojtas | Adam J Smith | Padmini Kavuru | R Douglas Shytle | Adam J. Smith | Padmini Kavuru
[1] P. Hollman,et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man , 1997, FEBS letters.
[2] W. Regelson,et al. Review of the biology of Quercetin and related bioflavonoids. , 1995, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[3] Ning Shan,et al. The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.
[4] S. Wolffram,et al. Bioavailability and metabolism of the flavonol quercetin in the pig. , 2000, Free radical biology & medicine.
[5] Allen H. Pekar,et al. Hybrid insulin cocrystals for controlled release delivery , 2002, Nature Biotechnology.
[6] A. Shete,et al. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride , 2010, Drug development and industrial pharmacy.
[7] J. Schellens,et al. Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] Jeanette T. Dunlap,et al. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.
[9] Orn Almarsson,et al. Performance comparison of a co-crystal of carbamazepine with marketed product. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[10] M. Zoratti,et al. Ester-based precursors to increase the bioavailability of quercetin. , 2007, Journal of medicinal chemistry.
[11] Sekhar Surapaneni,et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.
[12] I. R. Miksa,et al. Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[13] Akira Murakami,et al. Multitargeted cancer prevention by quercetin. , 2008, Cancer letters.
[14] G. Rimbach,et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. , 2008, The Journal of nutrition.
[15] Sandro Chiodo,et al. Iron chelation by the powerful antioxidant flavonoid quercetin. , 2006, Journal of agricultural and food chemistry.
[16] I. Erlund,et al. Bioavailability of Quercetin From Berries and the Diet , 2006, Nutrition and cancer.
[17] S. Wolffram,et al. Oral bioavailability of quercetin from different quercetin glycosides in dogs. , 2010, The British journal of nutrition.
[18] O. Texier,et al. Bioavailability of rutin and quercetin in rats , 1997, FEBS letters.
[19] J. Bernstein,et al. Graph-set analysis of hydrogen-bond patterns in organic crystals. , 1990, Acta crystallographica. Section B, Structural science.
[20] C. Auger,et al. Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats. , 2008, Journal of agricultural and food chemistry.
[21] G. Sheldrick. Phase annealing in SHELX-90: direct methods for larger structures , 1990 .
[22] M. Hertog. Epidemiological evidence on potential health properties of flavonoids , 1996, Proceedings of the Nutrition Society.
[23] Y. El‐Sayed,et al. Disposition of the Flavonoid Quercetin in Rats After Single Intravenous and Oral Doses , 2003, Drug development and industrial pharmacy.
[24] R. Burd,et al. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. , 2010, Nutrition reviews.
[25] M. Veit,et al. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. , 1999, International journal of clinical pharmacology and therapeutics.
[26] Aeri Park,et al. Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.
[27] Michael J. Zaworotko,et al. Structure―Stability Relationships in Cocrystal Hydrates: Does the Promiscuity of Water Make Crystalline Hydrates the Nemesis of Crystal Engineering? , 2010 .
[28] S. Wolffram,et al. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. , 2003, The Journal of nutrition.
[29] Chung S. Yang,et al. DOSE-DEPENDENT LEVELS OF EPIGALLOCATECHIN-3-GALLATE IN HUMAN COLON CANCER CELLS AND MOUSE PLASMA AND TISSUES , 2006, Drug Metabolism and Disposition.
[30] J. Pang,et al. Determination of in vitro permeability of drug candidates through a caco-2 cell monolayer by liquid chromatography/tandem mass spectrometry. , 2000, Journal of mass spectrometry : JMS.
[31] Allan S. Myerson,et al. Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals , 2011 .
[32] M. Morris,et al. Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[33] Orn Almarsson,et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.
[34] L. Howard,et al. Solubility and solution thermodynamic properties of quercetin and quercetin dihydrate in subcritical water , 2010 .
[35] J. Terao,et al. Quercetin's Solubility Affects Its Accumulation in Rat Plasma after Oral Administration† , 1998 .
[36] R. Gugler,et al. Disposition of quercetin in man after single oral and intravenous doses , 1975, European Journal of Clinical Pharmacology.
[37] Louis J. Farrugia,et al. WinGX suite for small-molecule single-crystal crystallography , 1999 .
[38] G. Jacobasch,et al. Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans , 2001, Journal of clinical pharmacology.
[39] Miranda L. Cheney,et al. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. , 2011, Journal of pharmaceutical sciences.
[40] O. Texier,et al. Comparison of the bioavailability of quercetin and catechin in rats. , 1999, Free radical biology & medicine.
[41] C. Rémésy,et al. Respective bioavailability of quercetin aglycone and its glycosides in a rat model. , 2000, BioFactors.
[42] C. Rice-Evans,et al. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. , 2003, The Biochemical journal.
[43] S. Wolffram,et al. Bioavailability of quercetin in pigs is influenced by the dietary fat content. , 2004, The Journal of nutrition.
[44] Amjad Alhalaweh,et al. Bioavailability of indomethacin‐saccharin cocrystals , 2010, The Journal of pharmacy and pharmacology.
[45] H. Choo,et al. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. , 2009, Bioorganic & medicinal chemistry.
[46] S. Velaga,et al. Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization , 2008, Pharmaceutical Research.